Lb Pharmaceuticals (LBRX) Cash from Operations (2024 - 2026)

Lb Pharmaceuticals' Cash from Operations history runs 3 years deep, the most recent figure standing at 23290000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 186.54% year-over-year to 23290000.0; the TTM figure through Mar 2026 stood at 55183000.0 (changed N/A YoY), while the FY2025 annual figure was 35200000.0, up 33.65% from the prior year.
• Cash from Operations was 23290000.0 for Q1 2026 at Lb Pharmaceuticals, down from 18100000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5665000.0 in Q4 2024 to a low of 23290000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 13795750.0 across 3 years, with a median of 13114000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Cash from Operations sank 219.51% in 2025, then slumped 186.54% in 2026.
• A 3-year view of Cash from Operations shows it stood at 5665000.0 in 2024, then tumbled by 219.51% to 18100000.0 in 2025, then fell by 28.67% to 23290000.0 in 2026.
• The last three Cash from Operations figures came in at 23290000.0 (Q1 2026), 18100000.0 (Q4 2025), and 8128000.0 (Q1 2025), per Business Quant data.